Dysautonomia (Autonomic Dysfunction) Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Dysautonomia (Autonomic Dysfunction) Market Size?
The market size of dysautonomia, or autonomic dysfunction, has seen a significant upturn lately. Its growth trajectory from $2.62 billion in 2024 to $2.92 billion in 2025, at an 11.5% compound annual growth rate (CAGR), demonstrates this. The previous progress can be linked to factors such as an upsurge in autonomic disorders, heightened awareness about dysautonomia, increased spending on healthcare, expanded research into neurodegenerative diseases, and elevated government backing for rare diseases.
The market size for dysautonomia (autonomic dysfunction) is predicted to witness quick expansion in the coming years. The projection is for it to reach $4.49 billion in 2029, with a compound annual growth rate (CAGR) of 11.4%. The expansion during the forecast period is linked to the increased uptake of personalized medicine, the escalation in clinical trials for innovative treatments, augmenting government funds for research on rare diseases, the growth of telemedicine and remote monitoring solutions, and the heightened availability of orphan drugs. Prominent trends for the forecast period encompass incorporation of artificial intelligence in diagnosis, generation of targeted treatments, usage of wearable devices for autonomic tracking, advancements in gene therapies, and ingenuity in patient-centric treatment methods.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21177&type=smp
Which Factors Are Steering Growth In The Dysautonomia (Autonomic Dysfunction) Market?
The dysautonomia (autonomic dysfunction) market is predicted to expand due to the increasing occurrence of chronic diseases. Chronic diseases, which are health conditions lasting more than three months, are on the rise due to factors such as a higher incidence of multimorbidity, where numerous chronic disorders are diagnosed simultaneously. Dysautonomia (autonomic dysfunction) significantly impacts chronic diseases, as it interrupts the body’s ability to control critical functions like heart rate, blood pressure, and digestion. This often magnifies the symptoms and complicates the management of these diseases. For example, a report from UK’s National Health Service in October 2023 showed that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, signifying a 3.5% year-over-year growth. Thus, the rise in chronic diseases is fuelling the expansion of the dysautonomia (autonomic dysfunction) market.
How Is The Dysautonomia (Autonomic Dysfunction) Market Organized By Different Segments?
The dysautonomia (autonomic dysfunction)market covered in this report is segmented –
1) By Type: Neurogenic Orthostatic Hypotension (NOH); Postural Orthostatic Tachycardia Syndrome (POTS); Multiple System Atrophy (MSA); Pure Autonomic Failure (PAF); Other Types
2) By Tests: Cardiovagal and Vasomotor Function Tests; Thermoregulatory Sweat Test (TST); Sympathetic Skin Response (SSR); Quantitative Sudomotor Axon Reflex Test; Other Tests
3) By Treatment: Physical Therapy; Exercise Therapy; Counseling; Other Treatments
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Clinics; Diagnostic Centers; Research Institutes
Subsegments:
1) By Neurogenic Orthostatic Hypotension (NOH): Primary NOH; Secondary NOH (due to Parkinson’s Disease, Diabetes, etc.); Pharmacological Management of NOH; Non-Pharmacological Interventions
2) By Postural Orthostatic Tachycardia Syndrome (POTS): Hyperadrenergic POTS; Hypovolemic POTS; Neuropathic POTS; Autoimmune POTS; Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
3) By Multiple System Atrophy (MSA): MSA-P (Parkinsonism); MSA-C (Cerebellar); MSA-A (Autonomic); Disease-Modifying and Symptomatic Treatment
4) By Pure Autonomic Failure (PAF): Idiopathic PAF; Secondary PAF (due to neurodegenerative diseases); Autonomic Supportive Treatments
5) By Other Types: Familial Dysautonomia (FD); Diabetic Autonomic Neuropathy; Horner’s Syndrome; Autoimmune Autonomic Ganglionopathy; Chronic Fatigue Syndrome-related Dysautonomia
What Current And Upcoming Trends Are Shaping The Dysautonomia (Autonomic Dysfunction) Market?
Major players in the dysautonomia (autonomic dysfunction) market are focused on improving gene therapy approaches, such as using recombinant adeno-associated virus (rAAV), to deliver therapeutic genes effectively and treat the root causes of dysautonomia. In January 2025, US-based Tikun Therapeutics Inc. received FDA Orphan Drug and Rare Pediatric Disease designations for two treatments: rAAV2-U1a-hELP1 (for familial dysautonomia-linked optic neuropathy) and BPN-36964 (a small molecule targeting systemic FD). These therapies are aimed at treating the genetic causes of FD, offering long-term benefits.
Who Are The Most Influential Companies In The Dysautonomia (Autonomic Dysfunction) Market?
Major companies operating in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children’s Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.
Access The Complete Report Here:
Which Region Dominates The Dysautonomia (Autonomic Dysfunction) Market Today?
North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dysautonomia (autonomic dysfunction) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21177&type=smp
Browse Through More Reports Similar to the Global Dysautonomia (Autonomic Dysfunction) Market 2025, By The Business Research Company
Drugs For Erectile Dysfunction Global Market Report 2025
Generic Central Nervous System Drugs Global Market Report 2025
Central Nervous System Biomarkers Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
